Contrasting Belite Bio (BLTE) and Its Rivals

Belite Bio (NASDAQ:BLTE) is one of 980 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Belite Bio to similar companies based on the strength of its analyst recommendations, valuation, institutional ownership, profitability, earnings, risk and dividends.

Volatility & Risk

Belite Bio has a beta of -1.62, indicating that its stock price is 262% less volatile than the S&P 500. Comparatively, Belite Bio’s rivals have a beta of 1.08, indicating that their average stock price is 8% more volatile than the S&P 500.

Institutional and Insider Ownership

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 14.3% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Belite Bio and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Belite Bio	N/A	-$31.63 million	-32.06
Belite Bio Competitors	$1.96 billion	$131.61 million	-4.25

Belite Bio’s rivals have higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Belite Bio and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0	0	7	0	3.00
Belite Bio Competitors	6240	18341	43530	893	2.57

Belite Bio presently has a consensus target price of $44.83, indicating a potential upside of 12.79%. As a group, “Pharmaceutical preparations” companies have a potential upside of 86.69%. Given Belite Bio’s rivals higher possible upside, analysts clearly believe Belite Bio has less favorable growth aspects than its rivals.

Profitability

This table compares Belite Bio and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-54.05%	-50.06%
Belite Bio Competitors	-2,642.48%	-232.29%	-29.78%

Summary

Belite Bio rivals beat Belite Bio on 9 of the 13 factors compared.

Belite Bio Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.